Alnylam Pharmaceuticals, Inc. (ALNY) Stock Analysis

65.0/100
Buy Not Halal Healthcare
Price $165.04
Market Cap $22.11B
52-Week Change -63.65%

Is ALNY a good investment?

Alnylam Pharmaceuticals, Inc. (ALNY) has a Plutrex AI rating of 65.0/100 as of November 09, 2026, indicating a Buy consensus. The stock is not classified as halal-compliant. Key strength: Profitability moat unmatched in sector: Net margin 54.3% vs. industry -0.04%, ROE 141.97% vs. industry -1.54%, FCF $500.7M — ALNY is one of approximately 5-10 truly self-funding profitable biotechs in a 137-company peer group dominated by cash burners; $3.59B cash means zero near-term existential risk. Main concern: Stock in confirmed technical freefall (-30.4% in 14 days, -30.4% from $224 to $156) with analyst target simultaneously reduced 12.6% — the combination of price collapse AND target cut suggests material negative news in the July 30, 2026 disclosure referenced in news analysis ('likely involved material negative news about operations, clinical trials, or financial performance'); revenue growth decelerated 75% from 66.9% to 16.7%, and near-term EPS projected -51.3%; entering a stock in this trajectory without clarity on the fundamental trigger of the selloff carries high timing risk.

Investment Summary

Alnylam Pharmaceuticals (ALNY) has experienced a catastrophic 30.4% price decline from $224.03 to $155.94 over the past 14 days, with the analyst consensus target simultaneously reduced 12.6% from $347.23 to $303.38 — a simultaneous price collapse AND target cut that signals something fundamental has changed, not merely market noise. The P/E ratio collapsed from 37.82x to 7.88x (a 79.2% compression) and revenue growth decelerated sharply from 66.9% to 16.7% (-75.0%) — these are not minor fluctuations but material deteriorations requiring a full reassessment. Despite this, ALNY retains elite profitability: net margin of 54.3% vs. industry average of -0.04%, ROE of 141.97% vs. industry -1.54%, gross margin of 77.3%, operating margin of 23.7%, and free cash flow of $500.7M against a $3.59B cash fortress. The PEG ratio of 0.11 vs. industry 2.26 makes it the cheapest growth stock in its 137-company biotech peer group. The core tension: extraordinary long-term fundamentals vs. a stock in confirmed technical freefall with material near-term earnings deterioration (-51.3% next-year EPS decline), a securities fraud investigation overhang, and a $1B share repurchase program that — while shareholder-friendly — may signal management's own view that the stock is severely undervalued at current levels.

Key Strengths

Key Concerns

Plutrex 10-Factor AI Breakdown

Financial Health
55/100
Growth Potential
70/100
Valuation
85/100
Profitability
90/100
Debt Management
40/100
Analyst Sentiment
65/100
Technical Momentum
25/100
Insider Confidence
55/100
News Sentiment
60/100

Fundamental Analysis

ALNY's fundamentals bifurcate sharply between exceptional quality and concerning near-term trajectory. PROFITABILITY (elite): Net margin 54.3% vs. industry -0.04% (effectively infinite premium); ROE 141.97% vs. industry -1.54%; gross margin 77.3% (at parity with industry 79.8%); operating margin 23.7% confirms genuine operational profitability — not accounting-driven. FINANCIAL HEALTH (mixed): Cash of $3.59B provides fortress-level liquidity; FCF of $500.7M (+$500.7M vs. most biotech peers burning cash) confirms business model works; however debt-to-equity of 0.64 vs. industry 0.24 is elevated (166.7% premium), and the near-term EPS decline creates forward balance sheet pressure if revenue disappoints. VALUATION (deeply discounted): P/E of 7.88x vs. industry 25.86x (-69.5% discount); PEG of 0.11 vs. industry 2.26 (-94.9% discount); analyst consensus $303.38 implies 94.5% upside — but the 12.6% target cut from $347.23 is a warning that analysts themselves are reducing expectations. GROWTH (bifurcated): Revenue growth decelerated sharply from 66.9% to 16.7% — a 75% deceleration that is the most alarming metric change in this period; next-year EPS -51.3% vs. industry +46.16% creates a 97.5 percentage point gap; 5-year EPS CAGR of 68.7% vs. industry 23.78% remains the bull case anchor but requires the near-term trough to be transient.

News Sentiment

Alnylam Pharmaceuticals is navigating one of its most turbulent stretches in recent memory, with shares tumbling more than 30% in two weeks as investors grapple with a mix of strategic shifts and clinical developments. The Cambridge-based RNA interference giant announced a $1 billion share repurchase program alongside a significant change in commercial leadership — a headline that reads bullish on the surface but arrives at a moment of maximum uncertainty. 'Alnylam Announces $1 Billion Share Repurchase Program and Change in Commercial Leadership' signals management believes the stock is deeply undervalued, yet the simultaneous leadership swap raises questions about why a commercial restructuring is needed now. On the science front, the company is set to present five-year HELIOS-B data, with the headline 'Alnylam to Present Five-Year HELIOS-B Data and Expanding Evidence' suggesting confidence in the durability of its flagship heart disease treatment — a critical datapoint for the embattled ATTR-CM franchise. Meanwhile, dose-dependent results from an ongoing trial show 'clinically meaningful pharmacological relationships,' giving the pipeline a credibility boost. Despite the turbulence, analysts expected Alnylam to beat Q3 earnings estimates — a headline that may have provided temporary relief — with 'Alnylam Pharmaceuticals Q3 Earnings Call Highlights' confirming the company did report results, though the official 'Q3 2026 Financial Results' release carried a neutral market reaction. The stock's selloff appears disproportionate to known news, suggesting investors are pricing in risks beyond what has been publicly disclosed.

Risk Assessment

PRIMARY RISK: The 30.4% decline in 14 days almost certainly traces to material undisclosed negative news (news analysis references a July 30, 2026 disclosure likely involving 'material negative news about operations, clinical trials, or financial performance'). Without knowing the precise trigger — ATTR-CM penetration miss, clinical setback, or securities litigation development — the full downside is not quantifiable. SECONDARY RISK: Near-term EPS -51.3% creates a trough where forward P/E expands significantly from the apparent 7.88x trailing multiple; if trailing earnings were inflated by one-time items (8,150% historical EPS growth suggests they were), normalized forward P/E could be 15-25x, reducing the apparent cheapness. TERTIARY RISK: Revenue growth deceleration from 66.9% to 16.7% in one period — if this continues to single digits, the 5-year EPS CAGR of 68.7% becomes mathematically implausible and the PEG thesis collapses. MITIGATION: $3.59B cash (23x the $155M market cap impact of a 1% price move), $500.7M FCF, and $1B buyback authorization provide substantial downside protection; stop at $135 limits loss to 10.9% from entry midpoint $151.50.

Related Halal Stocks

Related Stocks

Frequently Asked Questions

Is ALNY a halal stock?

No, Alnylam Pharmaceuticals, Inc. (ALNY) is currently not classified as halal by AAOIFI criteria.

What is Plutrex's AI rating for ALNY?

Alnylam Pharmaceuticals, Inc. (ALNY) has a Plutrex AI rating of 65.0/100 with a Buy consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.

Is ALNY a good investment?

According to Plutrex AI, ALNY has a Buy rating (65.0/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.

How can I invest in ALNY?

US stocks like ALNY can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. ElBarake provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.

What are the main risks of investing in ALNY?

Plutrex AI identifies the main risks for ALNY by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.

Chat with ElBarake AI about ALNY

Ask anything about this stock and get an instant AI-powered answer — free, no signup required.

Open ALNY in ElBarake